Ignite Creation Date:
2024-05-06 @ 3:51 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04775069
Status:
COMPLETED
Last Update Posted:
2023-10-04
First Post:
2021-02-24
Brief Title:
Antibody Response to COVID-19 Vaccines in Liver Disease Patients
Sponsor:
Humanity Health Medical Group Limited
Organization:
Humanity Health Medical Group Limited
Study Overview
Official Title:
A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA Inactivated Virus and Adenovirus Vector COVID-19 Vaccines
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Currently the Pfizer-Biontech mRNA Sinovac inactivated virus and Astrazeneca-Oxford adenovirus-vector COVID-19 vaccines are available for vaccination in HK The American Association of Liver Disease has recently published consensus statements for COVID-19 vaccination in subjects with chronic liver disease CLD Patients with CLD have dysregulated innate and adaptive immune response that may be associated with vaccine hypo-responsiveness and there are no data as to whether these patients may respond differently to the various vaccines The Humanity and Health Medical Center HHMC is an active participant of the HK government COVID-19 vaccination programs and patients with CLD follow-up at HHMC will have access to the three different vaccines The aim of this prospective study is to compare the antibody response of CLD subjects to the Pfizer-Biontech mRNA Sinovac inactivated virus and Astrazeneca-Oxford adenovirus-vector COVID-19 vaccines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None